Phaarmasia Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 306122, "name": "Phaarmasia", "stock_name": "Phaarmasia", "full_name": "Phaarmasia Ltd", "name_url": "stocks-analysis/phaarmasia", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "117.00", "chg": -2.96, "chgp": "-2.47%", "dir": -1, "prev_price": "119.96", "mcapval": "79.00 Cr", "mcap": "Micro Cap", "scripcode": 523620, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE486I01016", "curr_date": "Feb 12", "curr_time": "", "bse_nse_vol": "1.23 k", "exc_status": "Active", "traded_date": "Feb 12, 2026", "traded_date_str": "2026 02 12", "score": "", "scoreText": "", "Live": 1, "market_time": 1, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/phaarmasia-306122-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Phaarmasia Ltd Upgraded to Hold as Valuation and Technicals Improve", "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-upgraded-to-hold-as-valuation-and-technicals-improve-3829845", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PhaarmasiaLtd_mojoScore_3829845.png", "date": "2026-02-10 08:05:07", "description": "Phaarmasia Ltd has seen its investment rating upgraded from Sell to Hold, reflecting significant improvements across technical indicators and valuation metrics. The company’s recent financial performance, coupled with a bullish technical outlook and attractive valuation compared to peers, has prompted this reassessment by analysts as of 09 Feb 2026." }, { "title": "Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-valuation-shifts-signal-renewed-price-attractiveness-3829521", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PhaarmasiaLtd_valuationdot_3829521.png", "date": "2026-02-10 08:00:42", "description": "Phaarmasia Ltd has witnessed a significant re-rating in its valuation parameters, transitioning from a previously expensive profile to one now deemed attractive by market standards. This shift is underscored by a notable improvement in its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to both historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector." }, { "title": "Phaarmasia Ltd Gains 4.68%: Downgrade and Q2 Results Shape the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-gains-468-downgrade-and-q2-results-shape-the-week-3827094", "imagepath": "", "date": "2026-02-08 10:00:13", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock opens at Rs.99.00, Sensex down 1.03%</p>\n <p><strong>4 Feb:</strong> Stock drops 5.00% to Rs.94.05 following downgrade</p>\n <p><strong>5 Feb:</strong> MarketsMOJO downgrades Phaarmasia Ltd to Sell</p>\n <p><strong>6 Feb:</strong> Q2 FY26 results reveal sharp profit growth; stock rebounds to Rs.103.63</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.99.00</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.103...." }, { "title": "Are Phaarmasia Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-phaarmasia-ltd-latest-results-good-or-bad-3826807", "imagepath": "", "date": "2026-02-07 19:17:51", "description": "Phaarmasia Ltd's latest financial results present a mixed picture, highlighting both significant operational improvements in the most recent quarter and underlying structural challenges. In Q2 FY26, the company reported a net profit of ₹1.74 crores, a substantial increase compared to the previous quarter, alongside a remarkable revenue growth of 179.09% year-on-year, reaching ₹16.55 crores. This quarter also marked an operating margin of 9.73%, a notable recovery from a loss in the same quarter of the previous year.\n\nHowever, these positive results must be contextualized against the company's overall performance. For the fiscal year ending March 2025, Phaarmasia experienced a decline in net sales to ₹24.00 crores, down 20% from the previous year, and reported an operating loss of ₹2.00 crores. The recent quarterly spike in performance appears to be an anomaly rather than a sustained trend, as the company ha..." }, { "title": "Phaarmasia Ltd Q2 FY26: Sharp Turnaround Masks Deeper Structural Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/phaarmasia-ltd-q2-fy26-sharp-turnaround-masks-deeper-structural-concerns-3825054", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/Phaarmasia_quaterlyResult_3825054.png", "date": "2026-02-06 21:01:39", "description": "Phaarmasia Limited, a micro-cap pharmaceutical manufacturer specialising in oral contraceptive tablets, delivered a dramatic quarterly turnaround in Q2 FY26, posting net profit of ₹1.74 crores compared to a loss of ₹0.64 crores in the same quarter last year. The 140.90% sequential revenue surge to ₹16.55 crores and return to profitability triggered a 4.99% stock rally to ₹103.63, though the shares remain 21.34% below their 52-week high of ₹131.75." }, { "title": "Are Phaarmasia Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-phaarmasia-ltd-latest-results-good-or-bad-3824771", "imagepath": "", "date": "2026-02-06 19:20:20", "description": "Phaarmasia Ltd's latest financial results for Q2 FY26 reflect a significant turnaround in performance compared to previous periods. The company reported net sales of ₹16.55 crores, which marks a remarkable sequential growth of 140.90% from ₹6.87 crores in Q1 FY26 and a year-on-year increase of 179.09% from ₹5.93 crores in Q2 FY25. This surge in revenue is the highest quarterly figure recorded in at least two years, indicating a potential recovery in operational performance.\n\nNet profit for the quarter reached ₹1.74 crores, a stark contrast to the loss of ₹0.64 crores reported in the same quarter last year. This change represents a substantial improvement in profitability, with the profit after tax (PAT) margin increasing to 10.51% from a negative 10.79% year-on-year. Additionally, the operating margin, excluding other income, expanded to 9.73% from 1.16% in the previous quarter, showcasing enhanced operatio..." }, { "title": "Phaarmasia Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3821723", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/PhaarmasiaLtd_mojoScore_3821723.png", "date": "2026-02-05 08:03:46", "description": "Phaarmasia Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 4 February 2026, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments. Despite strong recent financial results and impressive long-term returns, concerns over weak fundamentals and expensive valuation have weighed heavily on the outlook." }, { "title": "When is the next results date for Phaarmasia Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-phaarmasia-ltd-3819088", "imagepath": "", "date": "2026-02-03 23:16:28", "description": "The next results date for Phaarmasia Ltd is scheduled for February 6, 2026...." }, { "title": "Phaarmasia Ltd is Rated Hold by MarketsMOJO", "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-hold-by-marketsmojo-3811212", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/PhaarmasiaLtd_mojoScore_3811212.png", "date": "2026-01-30 10:10:03", "description": "Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 18 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook." } ], "total": 713, "sid": "306122", "stock_news_url": "https://www.marketsmojo.com/news/phaarmasia-306122" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "09-Feb-2026", "details": "Newspaper Advertisement of unaudited Financial results for the Quarter ended 31st December 2025", "source": "BSE" }, { "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On Friday 06Th February 2026 At 05.00 PM", "datetime": "06-Feb-2026", "details": "Submission of Outcome of Board Meeting held on Friday 06th February 2026 at 05.00 PM for the Quarter ended 31 December 2025", "source": "BSE" }, { "caption": "Results-Financial Results For The Quarter Ended 31St December 2025", "datetime": "06-Feb-2026", "details": "Submission of Financial results for the Quarter ended 31st December 2025", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "No <strong>Dividend</strong> history available", "data": [] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock opens at Rs.99.00, Sensex down 1.03%

4 Feb: Stock drops 5.00% to Rs.94.05 following downgrade

5 Feb: MarketsMOJO downgrades Phaarmasia Ltd to Sell

6 Feb: Q2 FY26 results reveal sharp profit growth; stock rebounds to Rs.103.63

Read full news article

Are Phaarmasia Ltd latest results good or bad?

2026-02-07 19:17:51

Phaarmasia Ltd's latest financial results present a mixed picture, highlighting both significant operational improvements in the most recent quarter and underlying structural challenges. In Q2 FY26, the company reported a net profit of ₹1.74 crores, a substantial increase compared to the previous quarter, alongside a remarkable revenue growth of 179.09% year-on-year, reaching ₹16.55 crores. This quarter also marked an operating margin of 9.73%, a notable recovery from a loss in the same quarter of the previous year. However, these positive results must be contextualized against the company's overall performance. For the fiscal year ending March 2025, Phaarmasia experienced a decline in net sales to ₹24.00 crores, down 20% from the previous year, and reported an operating loss of ₹2.00 crores. The recent quarterly spike in performance appears to be an anomaly rather than a sustained trend, as the company ha...

Read full news article

Phaarmasia Ltd Q2 FY26: Sharp Turnaround Masks Deeper Structural Concerns

2026-02-06 21:01:39

Phaarmasia Limited, a micro-cap pharmaceutical manufacturer specialising in oral contraceptive tablets, delivered a dramatic quarterly turnaround in Q2 FY26, posting net profit of ₹1.74 crores compared to a loss of ₹0.64 crores in the same quarter last year. The 140.90% sequential revenue surge to ₹16.55 crores and return to profitability triggered a 4.99% stock rally to ₹103.63, though the shares remain 21.34% below their 52-week high of ₹131.75.

Read full news article

Are Phaarmasia Ltd latest results good or bad?

2026-02-06 19:20:20

Phaarmasia Ltd's latest financial results for Q2 FY26 reflect a significant turnaround in performance compared to previous periods. The company reported net sales of ₹16.55 crores, which marks a remarkable sequential growth of 140.90% from ₹6.87 crores in Q1 FY26 and a year-on-year increase of 179.09% from ₹5.93 crores in Q2 FY25. This surge in revenue is the highest quarterly figure recorded in at least two years, indicating a potential recovery in operational performance. Net profit for the quarter reached ₹1.74 crores, a stark contrast to the loss of ₹0.64 crores reported in the same quarter last year. This change represents a substantial improvement in profitability, with the profit after tax (PAT) margin increasing to 10.51% from a negative 10.79% year-on-year. Additionally, the operating margin, excluding other income, expanded to 9.73% from 1.16% in the previous quarter, showcasing enhanced operatio...

Read full news article

Phaarmasia Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-02-05 08:03:46

Phaarmasia Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 4 February 2026, reflecting a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments. Despite strong recent financial results and impressive long-term returns, concerns over weak fundamentals and expensive valuation have weighed heavily on the outlook.

Read full news article

When is the next results date for Phaarmasia Ltd?

2026-02-03 23:16:28

The next results date for Phaarmasia Ltd is scheduled for February 6, 2026....

Read full news article

Phaarmasia Ltd is Rated Hold by MarketsMOJO

2026-01-30 10:10:03

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 18 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 January 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article